|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
An Open Label, Single Arm Study, to Evaluate the Safety and Efficacy of NDV01 KIT in Patients With High Grade Non Muscle Invasive Bladder Cancer (NMIBC)
High-grade NMIBC is more aggressive cancer that has a higher risk of progression and recurrence compared to low-grade NMIBC. NDV01 is a novel controlled release intravesical formulation designed for the treatment of non-muscle invasive bladder cancer (NMIBC).
100 Clinical Results associated with PSMA x DNA x RNR
100 Translational Medicine associated with PSMA x DNA x RNR
0 Patents (Medical) associated with PSMA x DNA x RNR